Bausch + Lomb Q4 Earnings Call Highlights

• Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value

Bausch + Lomb (NYSE:BLCO) executives highlighted what they described arsenic a grounds 4th fourth and full-year 2025 performance, driven by broad-based gross growth, accelerating profitability, and continued momentum successful adust oculus during the company’s fourth-quarter 2025 net call.

Chairman and CEO Brent Saunders said the institution “grew smarter and faster than the market,” pointing to 7% constant-currency gross growth successful the 4th fourth and 27% adjusted EBITDA growth arsenic grounds of “real operating leverage.” He noted the quarter’s $1.4 billion successful gross and $330 million successful adjusted EBITDA arsenic institution “high watermarks,” portion acknowledging the concern has seasonality, with the archetypal 4th typically the lowest and the 4th fourth the highest.

→ Meta's Platfroms' New Bull: Why Billionaire Bill Ackman Is Buying

• It’s Time To Nibble On These Two Recent IPOs

CFO Sam Eldessouky reported full institution gross of $1.405 billion successful the 4th quarter, up 7% connected a constant-currency basis. Full-year gross was $5.101 billion, up 5%, and up 6% excluding the enVista recall. Currency was a tailwind of astir $37 million successful the 4th and $58 million for the afloat year.

Adjusted EBITDA successful the 4th fourth was $330 million, up 27%, with an adjusted EBITDA borderline of 23.5%, which Eldessouky said was the highest level the institution has achieved arsenic a standalone institution since its IPO. Full-year adjusted EBITDA was $891 million, and adjusted EBITDA borderline for the afloat twelvemonth was 17.5%.

→ Whale Watching: BlackRock’s Massive Bet connected Nebius Group

In Vision Care, fourth-quarter gross was $778 million, up 5%, with full-year gross of $2.923 billion, up 6%. The user concern roseate 3% successful the 4th and 5% for the year. Eldessouky cited:

• Lumify gross of $63 million successful Q4 (up 24%) and $221 million for the twelvemonth (up 16%)

• Consumer adust oculus portfolio gross of $116 million successful Q4 (up 6%), led by Blink maturation of 33%

• Full-year user adust oculus gross of $436 million (up 14%)

Contact lens gross accrued 8% successful Q4 and 7% for the afloat year, led by regular silicone hydrogel (SiHy), which roseate 17% successful Q4 and 28% for the year. The institution said the U.S. interaction lens concern grew 11% successful Q4 and 9% for the year, portion planetary grew 6% successful Q4 and 5% for the year. In China, interaction lenses grew 7% successful Q4 and 8% for the afloat year.

→ Devon Energy Bets connected Scale With Coterra Acquisition

Surgical conception gross was $249 million successful Q4, up 3% (or 6% excluding the interaction of the enVista recall). Full-year surgical gross was $894 million, up 4% (or 10% excluding the recall). Eldessouky said premium intraocular lenses (IOLs) grew 20% successful Q4 and 26% for the year.